Marshall Wace’s X4 Pharmaceuticals XFOR Stock Holding History

Marshall Wace’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.39M	Buy	336,834 +256,378	+319%	+$960K	﹤0.01%	1974
2025 Q4	$322K	Buy	+80,456	New	+$292K	﹤0.01%	2425
2023 Q4	–	Sell	-430	Closed	-$14.1K	–	2659
2023 Q3	$14.1K	Sell	430 -23,048	-98%	-$1.01M	﹤0.01%	2120
2023 Q2	$1.37M	Buy	+23,478	New	+$1.21M	﹤0.01%	1596
2022 Q2	–	Sell	-437	Closed	-$23K	–	3911
2022 Q1	$23K	Sell	437 -1,579	-78%	-$90.6K	﹤0.01%	3261
2021 Q4	$139K	Buy	2,016 +1,175	+140%	+$149K	﹤0.01%	3286
2021 Q3	$133K	Buy	841 +384	+84%	+$63.2K	﹤0.01%	2855
2021 Q2	$89K	Buy	+457	New	+$115K	﹤0.01%	2543

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Marshall Wace's XFOR Position: Q1 2026 in Review

Marshall Wace increased its X4 Pharmaceuticals (XFOR) stake by 319% in Q1 2026, buying an estimated $960K and bringing the position to 336,834 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

Marshall Wace first reported a position in XFOR in Q2 2021 and has held it in 8 quarters since. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Marshall Wace held 336,834 shares of X4 Pharmaceuticals worth $1.39M as of Q1 2026.
Marshall Wace bought 256,378 X4 Pharmaceuticals shares in Q1 2026, an estimated $960K.
X4 Pharmaceuticals made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1974 holding.
Marshall Wace first reported a position in X4 Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.